SAM #BAA-23-100-SOL-00004

Award for development of SCY-247, a novel antifungal for invasive candidiasis and fungal disease prophylaxis

This award from the Biomedical Advanced Research and Development Authority (BARDA), under the Department of Health and Human Services, supports the development of a novel antifungal drug. - Government Buyer: - Department of Health and Human Services - Office of Assistant Secretary for Preparedness and Response - Biomedical Advanced Research and Development Authority (BARDA) - OEM and Vendor: - Scynexis, Inc. (manufacturer and awardee) - Products/Services Requested: - Development of SCY-247, a novel antifungal drug - Target indications: invasive candidiasis treatment and prophylaxis of invasive fungal disease - Formulations: oral and intracavitary (IC) - Phase 1 clinical trials - Unique/Notable Requirements: - Focus on advancing a new pharmaceutical agent for critical infectious disease indications - No specific part numbers or purchase quantities; this is a research and development award - Award Value: - $213,943,726 - No additional product or service line items listed

View original listing